InflaRx NV, a clinical-stage biopharmaceutical company headquartered in Jena, Germany, continues to make strides in the biotechnology sector, focusing on the discovery and development of monoclonal antibody drugs aimed at treating inflammatory diseases. As a key player in the health care industry, InflaRx NV serves a global patient base, leveraging its innovative approach to address unmet medical needs in inflammation-related conditions.

The company is publicly traded on the Frankfurt Stock Exchange, with its shares denominated in euros (EUR). As of October 23, 2025, InflaRx NV’s closing price stood at 1.015 EUR. Over the past year, the company’s stock has experienced significant volatility, reaching a 52-week high of 2.618 EUR on December 5, 2024, and a 52-week low of 0.623 EUR on May 27, 2025. This fluctuation reflects the dynamic nature of the biotechnology sector and the market’s response to the company’s developmental milestones and broader industry trends.

InflaRx NV’s market capitalization, as of the latest data, is approximately 68,140,270 EUR. This valuation underscores the company’s position within the biopharmaceutical landscape and its potential for growth as it progresses through various stages of drug development and commercialization.

Since its initial public offering (IPO) on November 8, 2017, InflaRx NV has been committed to advancing its pipeline of monoclonal antibody therapies. These therapies are designed to target specific pathways involved in inflammatory processes, offering the potential for more effective and targeted treatment options for patients suffering from a range of inflammatory diseases.

The company’s strategic focus on monoclonal antibodies is driven by the growing recognition of the role of inflammation in numerous chronic diseases. By developing therapies that can modulate the immune system’s response, InflaRx NV aims to provide innovative solutions that improve patient outcomes and quality of life.

InflaRx NV’s efforts are supported by a robust pipeline of investigational drugs, each at various stages of clinical development. The company’s commitment to rigorous scientific research and development is evident in its ongoing clinical trials, which are designed to evaluate the safety, efficacy, and potential of its therapeutic candidates.

As InflaRx NV continues to navigate the complexities of drug development, it remains focused on its mission to deliver transformative therapies to patients worldwide. The company’s dedication to innovation and patient care positions it as a significant contributor to the advancement of biopharmaceuticals in the treatment of inflammatory diseases.

For more information about InflaRx NV and its developments, stakeholders and interested parties are encouraged to visit the company’s official website at www.inflarx.de .